Relatlimab

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.

Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. It is under development by Bristol-Myers Squibb. It is made using Chinese hamster ovary cells.

History
, relatlimab is undergoing Phase II/III trials.

The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.

Names
Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).